Glaukos Corporation (GKOS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Glaukos Corporation (GKOS)
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Key Insights
Critical company metrics and information
Share Price
$138.69Market Cap
$7.65 BillionTotal Outstanding Shares
55.14 Million SharesTotal Employees
907Dividend
No dividendIPO Date
June 25, 2015SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.glaukos.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-10.64 Million |
Net Cash Flow From Investing Activities, Continuing | $23.12 Million |
Net Cash Flow From Investing Activities | $23.12 Million |
Net Cash Flow From Operating Activities, Continuing | $-72.49 Million |
Net Cash Flow From Operating Activities | $-72.49 Million |
Net Cash Flow, Continuing | $-10.64 Million |
Net Cash Flow From Financing Activities | $38.73 Million |
Net Cash Flow From Financing Activities, Continuing | $38.73 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Earnings Per Share | $-2.96 |
Costs And Expenses | $508.97 Million |
Operating Expenses | $408.39 Million |
Other Operating Expenses | $153.19 Million |
Operating Income/Loss | $-132.32 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-149.57 Million |
Gross Profit | $276.06 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income Tax Expense/Benefit | $946,000.00 |
Income/Loss From Continuing Operations After Tax | $-149.57 Million |
Net Income/Loss | $-149.57 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Earnings Per Share | $-2.96 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Parent | $-149.57 Million |
Revenues | $360.35 Million |
Income/Loss From Continuing Operations Before Tax | $-148.63 Million |
Diluted Average Shares | $51.95 Million |
Selling, General, and Administrative Expenses | $255.20 Million |
Basic Average Shares | $51.95 Million |
Benefits Costs and Expenses | $508.97 Million |
Nonoperating Income/Loss | $-16.30 Million |
Cost Of Revenue | $84.28 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Non-current Assets | $161.26 Million |
Inventory | $59.90 Million |
Equity | $668.51 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Current Assets | $397.28 Million |
Equity Attributable To Parent | $668.51 Million |
Other Current Assets | $337.39 Million |
Noncurrent Assets | $529.26 Million |
Other Current Liabilities | $60.58 Million |
Intangible Assets | $269.42 Million |
Liabilities And Equity | $926.54 Million |
Accounts Payable | $11.10 Million |
Assets | $926.54 Million |
Fixed Assets | $98.58 Million |
Current Liabilities | $71.68 Million |
Noncurrent Liabilities | $186.35 Million |
Liabilities | $258.03 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.